ODTx
OnDemand Therapeutics, Inc. is an early stage, venture-backed medical device company. ODTx invented and patented a new way to deliver intraocular drug therapies to treat retinal conditions.
The ODTx drug delivery concept. Laser light is directed to a surgically implanted drug delivery device in the posterior chamber of the eye. The laser light opens and activates the release of a selected pharmaceutical agent in an "on-demand" fashion.
ODTx drug delivery technology employs a surgically-implantable device that contains one or more drug-containing micro-reservoirs. At the time of a physician's choosing, a standard ophthalmic photocoagulator laser instrument is used to direct laser light at a desired micro-reservoir. The activation process releases controlled amounts of drug into the posterior chamber of the eye, enabling the physician to control the timing and nature of intraocular therapy. The ODTx approach was developed to treat ocular diseases such as macular degeneration, diabetic retinopathy or uveitis. You can learn more about ODTx technology here.
Prototype ODTx device in vitro after laser activation by Gain Consulting personnel. Green and red areas show elution of fluorescently-marked drug analogues in solution.
Gain Consulting also assisted in the development and presentation of materials leading to successful Series A funding rounds from InterWest Partners.
Gain Consulting led the initial proof of concept project for ODTx. Gain Consulting developed the laser-material interaction, qualified the fluorophotometry technique for pharmacokinetic and pharmacodynamic measurements, and performed the laser procedures in the initial animal studies of a prototype laser-activated drug delivery device. In collaboration with other ODTx personnel, Gain Consulting co-developed new IP ('426, '804) covering laser activation of drug release.
Prototype device eluting fluorescently-labeled drugs in a live rabbit model. Laser activation performed by Gain Consulting personnel.